OLIGOFASTX is an R&D project carried out by a multidisciplinary business consortium of Spanish companies with expertise in technologies related to the development of oligonucleotide-based drugs.


The project seeks therapeutic solutions for seven rare diseases. It is funded by the Centre for the Development of Industrial Technology (CDTI) through the Science and Innovation Missions programme, within the Recovery, Transformation and Resilience Plan – Next Generation EU Funds.


With a duration of more than three years, OLIGOFASTX will address the design and research of new therapies for Retinitis Pigmentosa, Guillain-Barré Syndrome, Leber Congenital Amaurosis, Cachexia Cancer, Alström Syndrome, Fuchs Endothelial Corneal Dystrophy and Anaplastic Thyroid Cancer.

Participating companies:

The seven entities that make up the consortium are specialised in the different activities needed to complete the oligonucleotide-based drug development cycle, creating the industrial fabric necessary for the emergence of new RNA-based therapies.